SELLAS Life Sciences
29 hedge funds and large institutions have $21.3M invested in SELLAS Life Sciences in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 7 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
98% more call options, than puts
Call options by funds: $3.98M | Put options by funds: $2.01M
61% more capital invested
Capital invested by funds: $13.3M → $21.3M (+$8.03M)
2.28% more ownership
Funds ownership: 10.29% → 12.58% (+2.3%)
6% less funds holding
Funds holding: 31 → 29 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.45M |
| 2 |
JG
Jefferies Group
New York
|
+$1.28M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.07M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$697K |
| 5 |
State Street
Boston,
Massachusetts
|
+$366K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$1.11M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$410K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$266K |
| 4 |
VF
Virtu Financial
New York
|
-$125K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$113K |
SLS Hedge Fund Activity: Q2 2021 in Review
29 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2021, worth a combined $21.3M — up 61% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SLS and 5 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 13 added.
The largest buyer was Vanguard Group, adding an estimated $1.45M. The largest seller was Nomura Holdings, exiting entirely with an estimated $1.11M sold.
- 29 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2021, down from 31 in Q1 2021.
- Funds reported $21.3M of SELLAS Life Sciences stock for Q2 2021, up 61% quarter-over-quarter.
- 5 funds opened new SELLAS Life Sciences positions in Q2 2021 and 7 closed out, a net change of -2 holders.
- The largest SELLAS Life Sciences buyer in Q2 2021 was Vanguard Group, an estimated $1.45M added.
- The largest SELLAS Life Sciences seller in Q2 2021 was Nomura Holdings, an estimated $1.11M sold.
Based on aggregated 13F filings for Q2 2021.